| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2019: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2018: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Outline of Final Research Achievements |
In Japanese cases with dura-grafted CJD, we identified the ratio of M1 prion and V2 prion similarly as the ratio of European sporadic CJD. However, the ratio of European cases with Growth hormone-associated CJD was quite different from the ratio of European sporadic CJD. Because the infection route is different between both infections, we compared the infection between intracranial and intraperitoneal administration. In intracranial administration, 100% of knock-in mice were infected with M1 or V2 prion. However, in intraperitoneal administration, M1 prion-infected mice were fewer than V2-infected mice. In particular, the knock-in mice with 129Met/Met were hardly infected with M1 prions. These results well explain the different ratio between dura grafted CJD and growth hormone associated CJD.
|
